Use of transcriptome modifying agents and chemotherapy or radiotherapy against cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 17, 2015
Grant Date -
Aug 6, 2009
app pub date -
Nov 16, 2005
filing date -
Nov 16, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The use of transcriptome-modifying agents is disclosed in order to prevent malignant cells from undergoing the necessary genetic changes in order to combat cell insult and survive chemotherapy or radiotherapy. The combination of transcriptome-modifying agents comprises agents that inhibit the DNA methylation machinery plus a substance that inhibits histone deacetylation. A treatment kit is disclosed which includes an effective dose of hydralazine and valproic acid or a salt of same in the case of magnesium valproate, which is intended for use with radiotherapy or chemotherapy in the treatment of patients cancer.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully